1. Home
  2. ONL vs IMUX Comparison

ONL vs IMUX Comparison

Compare ONL & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Orion Office REIT Inc.

ONL

Orion Office REIT Inc.

HOLD

Current Price

$2.19

Market Cap

165.4M

Sector

Real Estate

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$7.40

Market Cap

155.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ONL
IMUX
Founded
2021
2016
Country
United States
United States
Employees
N/A
66
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
165.4M
155.8M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
ONL
IMUX
Price
$2.19
$7.40
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $43.09
AVG Volume (30 Days)
333.0K
★ 382.7K
Earning Date
11-05-2026
11-12-2026
Dividend Yield
★ 3.72%
N/A
EPS Growth
N/A
★ 38.00
EPS
★ 0.19
N/A
Revenue
★ $147,647,000.00
N/A
Revenue This Year
$1.67
N/A
Revenue Next Year
$0.11
N/A
P/E Ratio
$11.21
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.89
$0.51
52 Week High
$3.05
$17.43

Technical Indicators

Market Signals
Indicator
ONL
IMUX
Relative Strength Index (RSI) 42.49 36.21
Support Level $1.91 $6.35
Resistance Level $2.59 $8.60
Average True Range (ATR) 0.08 0.65
MACD 0.01 0.19
Stochastic Oscillator 52.75 46.67

Price Performance

Historical Comparison
ONL
IMUX

About ONL Orion Office REIT Inc.

Orion Properties Inc is an internally managed real estate investment trust engaged in the ownership, acquisition, and management of a diversified portfolio of office properties located in high-quality suburban markets across the United States and leased mainly on a single-tenant net lease basis to creditworthy tenants. Its portfolio is comprised of traditional office properties, as well as governmental, medical office, flex/laboratory, and R&D and flex/industrial properties. The company is focused on shifting its portfolio concentration over time away from traditional office properties, towards more dedicated use assets with specialized uses that include an office component. It operates in one business segment: commercial real estate.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: